Bellaire Dermatology Associates | Bellaire, TX

Research site

(Unclaimed)

Location

6565 West Loop South Suite 800, Bellaire, Texas, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

Dupilumab

TAK-279

Remibrutinib

Lebrikizumab

MT10109L

AGN-151586

Rocatinlimab

Tirzepatide

Ixekizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 54 total trials

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in pa...

Active, not recruiting

Hidradenitis Suppurativa

Drug: Placebo 1

Drug: Placebo 2

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo (VITESS)

The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632...

Enrolling

Non-segmental Vitiligo

Drug: Placebo

Drug: GIA632

A Post Market Device Study for the Treatment of Acne

To evaluate the safety and efficacy of the Cutera laser system for the treatment of acne vulgaris.

Active, not recruiting

Acne Vulgaris

Device: Cutera Laser System

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Active, not recruiting

Plaque Psoriasis

Drug: TAK-279

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling

Atopic Dermatitis

Drug: Upadacitinib 30mg Dose

Drug: Upadacitinib 15mg Dose

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Active, not recruiting

Vitiligo

Other: NB-UVB (narrow-band ultraviolet B) Phototherapy

Drug: Placebo

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Active, not recruiting

Hidradenitis Suppurativa

Drug: Upadacitinib

Drug: Placebo

Locations recently updated

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa (Intrepid)

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Active, not recruiting

Hidradenitis Suppurativa

Drug: Placebo

Drug: Lutikizumab

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines (RECLAIM)

This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\]...

Enrolling

Chronic Spontaneous Urticaria (CSU)

Drug: Placebo solution for injection

Drug: Dupilumab

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling

Alopecia Areata

Drug: Placebo

Drug: Upadacitinib

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participan...

Enrolling

Psoriasis

Overweight or Obesity

Drug: Tirzepatide